Sana Biotechnology (NASDAQ:SANA) Issues Earnings Results, Beats Estimates By $0.02 EPS

by · The Markets Daily

Sana Biotechnology (NASDAQ:SANA – Get Free Report) released its earnings results on Monday. The company reported ($0.13) EPS for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.02, FiscalAI reports.

Sana Biotechnology Price Performance

Sana Biotechnology stock traded up $0.09 during mid-day trading on Monday, hitting $3.61. The company’s stock had a trading volume of 2,724,461 shares, compared to its average volume of 3,150,903. The stock has a market cap of $1.00 billion, a price-to-earnings ratio of -3.88 and a beta of 2.16. The business has a 50 day moving average price of $3.30 and a 200-day moving average price of $3.48. Sana Biotechnology has a 12 month low of $2.61 and a 12 month high of $6.55.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. Mercer Global Advisors Inc. ADV bought a new stake in shares of Sana Biotechnology in the 3rd quarter valued at about $36,000. Russell Investments Group Ltd. bought a new position in Sana Biotechnology during the 3rd quarter worth approximately $39,000. Jacobi Capital Management LLC bought a new position in Sana Biotechnology during the 4th quarter worth approximately $41,000. BNP Paribas Financial Markets increased its stake in Sana Biotechnology by 46.9% in the 2nd quarter. BNP Paribas Financial Markets now owns 15,444 shares of the company’s stock worth $42,000 after purchasing an additional 4,931 shares during the period. Finally, Captrust Financial Advisors increased its stake in Sana Biotechnology by 43.8% in the 2nd quarter. Captrust Financial Advisors now owns 15,793 shares of the company’s stock worth $43,000 after purchasing an additional 4,807 shares during the period. 88.23% of the stock is owned by institutional investors.

Analysts Set New Price Targets

SANA has been the subject of a number of research reports. Rodman & Renshaw began coverage on Sana Biotechnology in a report on Monday, May 11th. They issued a “buy” rating and a $16.00 price objective for the company. Wedbush increased their price objective on Sana Biotechnology from $6.00 to $7.00 and gave the company an “outperform” rating in a research report on Tuesday, April 14th. Weiss Ratings raised Sana Biotechnology from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, July 23rd. Finally, Wall Street Zen downgraded Sana Biotechnology from a “hold” rating to a “sell” rating in a research report on Monday, July 20th. Seven analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $9.50.

Check Out Our Latest Analysis on Sana Biotechnology

About Sana Biotechnology

(Get Free Report)

Sana Biotechnology is a clinical-stage biopharmaceutical company focused on the development of engineered cells as medicines with the goal of treating a broad range of diseases. The company applies advanced gene editing and gene delivery technologies to create next-generation cell therapy products for oncology, genetic disorders and other serious diseases. By leveraging both ex vivo and in vivo approaches, Sana aims to repair or replace damaged cells and restore healthy tissue function.

The company’s core platform integrates proprietary gene writing capabilities alongside established gene editing tools such as CRISPR–Cas9.

Featured Stories